ZNF185

Across TCGA pan-cancer cohorts, ZNF185 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ZNF185 data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF185 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ZNF185 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where ZNF185 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	0.911	0.662	.005	66	view →
PDAC	DFS	Tertile	II,III,IV	0.269	0.472	.003	55	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.891	.021	3	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.839	.033	3	view →
GBM	OS	Median	All	0.444	0.647	.020	3	view →
CCRCC	OS	Median	III,IV	1.000	0.353	.022	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ZNF185–HNSC (DFS)

Open the HNSC breakdown →